Nintedanib open-label extension study in PF-ILD (progressive fibrosing) - active arm continuing: similar rate of change as RCT (78 v 77) - placebo arm initiating: similar as well Missing data (COVID-19) but effect appears related to exposure INBUILD-ON #ACR21 ABST0186 @RheumNow https://t.co/hWe7ypbex6